Terapia cellulare e molecolare sperimentale del diabete mellito di tipo 1 con cellule staminali: stato attuale

Abstract

Advances in cell and molecular technology have fostered development of innovative approaches to manage type 1 diabetes mellitus. The main focus is to replace destroyed β cells by induced pluripotent-(hiPSC) and/or mesenchymal stem cells (hMSC) thanks to multi-step differentiation protocols. The aim is to obtain β-like cells invisible to the host's immune system by their physical envelopment within recombinant, last generation biopolymers that prevent contact between embodied cells and host’s immune system, thereby avoiding recipient’s general immunosuppression with its global side effects.